Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

Abramson, Jeremy S.; Johnston, Patrick B.; Kamdar, Manali; Ibrahimi, Sami; Izutsu, Koji; Arnason, Jon; Glaß, Bertram; Mutsaers, Pim G.N.J.; Lunning, Matthew A.; Braverman, Julia; Liu, Fei Fei; Crotta, Alessandro; Montheard, Sandrine; Previtali, Alessandro; Guo, Shien; Shi, Ling; Solomon, Scott R.

doi:10.1182/bloodadvances.2022008106

Cited by 10 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 12 , 13 In TRANSFORM, 18% of patients experienced a decline in cognition at 6 months, assessed by the EORTCT‐QLQC30 cognitive items. 39 Our results support the stability of perceived cognitive function over time.…”

Section: Discussionsupporting

confidence: 79%

“…However, the number of questionnaires was a barrier to exhaustive completion and may induce a nonresponse bias. We chose to explore HRQoL in responding patients, especially in line with clinical trials that analyzed responders separately from nonresponders, but this may induce a survivor bias 4,5,61 . Also, the sample's relative heterogeneity may limit our capacity to generalize our findings: our patient population comprised aggressive and indolent lymphomas with different treatment histories.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?

Perthus,

Colin,

Charton

et al. 2024

HemaSphere

View full text Add to dashboard Cite

Chimeric antigen receptor T cells (CAR T cells) can induce prolonged remission in a substantial subset of patients with relapse/refractory lymphoma. However, little is known about patients' life after CAR T‐cell therapy. We prospectively assessed the multidimensional recovery of lymphoma patients in remission, before leukapheresis, before CAR T‐cell infusion, and 3, 6, and 12 months thereafter. Validated tools were used to measure lymphoma‐related and global health‐related quality of life (HRQoL; Functional Assessment of Cancer Therapy‐Lymphoma [FACT‐Lym] and EQ‐5D‐5L), cognitive complaint (FACT‐Cognition), fatigue (FACIT‐Fatigue subscale), psychological status (Hospital Anxiety and Depression Scale, Post‐Traumatic Check List Scale), and sexuality (Relationship and Sexuality Scale). Beyond 12 months of remission, we also surveyed physical, professional, sexual, and general life status. At 3, 6, and 12 months, 53, 35, and 23 patients were evaluable, respectively. Improvement in lymphoma‐related HRQoL was clinically relevant at 3, 6, and 12 months with a mean change from baseline of 10.9 (95% confidence interval [CI]: 5.8; 16.1), 12.2 (95% CI: 4.2; 20.1), and 11.72 (95% CI: 2.06; 21.38), respectively. Improvement in global HRQoL, fatigue, and anxiety was clinically relevant, but 20%–40% of patients experienced persistent fatigue, psychological distress, and cognitive complaints over time. Beyond 12 months after CAR T cells, 81.8% of 22 evaluable patients were satisfied with their daily life. Physical activity, professional, sexual, and global well‐being had returned to prediagnosis levels in nearly half of the patients. We found an improvement in HRQoL after CAR T‐cell therapy including anxiety, depression, sexual satisfaction, and general well‐being. However, not all patients recover a “normal life.” Further research is needed to determine which patients are at risk of quality‐of‐life impairment to improve recovery after CAR T‐cell infusion.

show abstract

Section: Discussionsupporting

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?

Perthus,

Colin,

Charton

et al. 2024

HemaSphere

View full text Add to dashboard Cite

show abstract

“…However, the emergence of novel therapies, such as Venetoclax and chimeric antigen receptor T‐cell therapy (CAR‐T therapy), has changed this concept 5 . In particular, CAR‐T therapy has significantly improved the prognosis of relapsed and refractory DLBCL (rrDLBCL) with an objective remission rate (ORR) of more than 80% 6,7 . Numerous CAR‐T therapies have also been launched recently in China with an ORR reaching over 60% 8,9 .…”

Section: Introductionmentioning

confidence: 99%

“… 5 In particular, CAR‐T therapy has significantly improved the prognosis of relapsed and refractory DLBCL (rrDLBCL) with an objective remission rate (ORR) of more than 80%. 6 , 7 Numerous CAR‐T therapies have also been launched recently in China with an ORR reaching over 60%. 8 , 9 Therefore, the current study aimed to evaluate the prognosis of TP53mut patients in the context of CAR‐T therapy and to explore the heterogeneity in their cohort and identify the possible risk factors.…”

Section: Introductionmentioning

confidence: 99%

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high‐risk subgroup represented by the co‐mutations of DDX3X‐TP53

Gao

Hu²,

Zheng³

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

Background TP53 mutations have a prognostic significance in relapsed and refractory diffuse large B‐cell lymphoma (rrDLBCL) patients, and their treatment still faces a great challenge. This study aimed to evaluate the prognosis of patients with TP53 mutations (TP53mut) in the context of CAR‐T therapy (Chimeric antigen receptor T‐cell therapy) as well as explore the heterogeneity in their cohort and identify the possible risk factors. Methods A retrospective study was conducted to investigate the clinical characteristics of rrDLBCL patients with TP53 mutations and their prognostic factors, receiving CAR‐T therapy. And the expression level of TP53 and DDX3X, which was an important co‐mutation of TP53 revealed in the cohort, were explored in public databases and cell lines. Results The median overall survival time of 40 patients with TP53 mutations was 24.5 months, while their median progression‐free survival time after CAR‐T was 6.8 months. There were no significant differences in the ORR (objective remission rate, X2 = 3.0498, p > 0.05) and PFS (after CAR‐T therapy) between the patients with wild‐type and mutated TP53 genes after CAR‐T therapy, while the OS of patients with TP53 mutations was significantly worse (p < 0.01). In patients with TP53 mutations, the performance status (ECOG score) was identified as the most important prognostic factor, while the efficacies of induction and salvage treatments were also correlated with the prognosis. Among molecular indicators, the co‐mutations of Chr‐17 and those located on the exon 5 of the TP53 gene showed a tendency for a worse prognosis. Moreover, the patients with TP53‐DDX3X co‐mutations were identified as a subgroup with an extremely bad prognosis. The expression levels of DDX3X and TP53 were explored in a public database and the cell lines with their co‐mutations, which indicated that inhibiting the DDX3X gene could affect the proliferation of rrDLBCL cells and the expression of TP53. Conclusions This study indicated rrDLBCL patients with TP53 mutations was still the group of poor prognosis in the CAR‐T therapy era. CAR‐T therapy can benefit some TP53mut patients, and the performance status (ECOG) might help predict their prognosis. The study also revealed a subgroup of TP53‐DDX3X co‐mutations in rrDLBCL, which showed a strong clinical significance.

show abstract

“…21 An analysis of the parameters related to the quality of life (QoL) showed that the Liso-Cel arm showed a higher improvement in QoL parameters and a lower deterioration than the SOC arm. 22 Olson and coworkers explored tumor biology and microenvironment from lymph node biopsies of DLBCL patients undergoing treatment with Liso-Cel. The authors compared gene expression profiles between responding and non-responding patients.…”

mentioning

confidence: 99%

Car-T Cell Therapy in Large B Cell Lymphoma

Testa,

Castelli,

Leone

et al. 2023

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Large B-cell lymphomas (LBCLs) are among the most frequent (about 30%) non-Hodgkin’s lymphoma. Despite the aggressive behavior of these lymphomas, more than 60% of patients can be cured with first-line chemoimmunotherapy using the R-CHOP regimen. Patients with refractory or relapsing disease show a poor outcome even when treated with second-line therapies. CD19-targeted chimeric antigen receptor (CAR) T-cells are emerging as an efficacious second-line treatment strategy for patients with LBCL. Three CD19-CAR-T-cell products received FDA and EMA approval. The use of CAR-T cell therapy has also been explored for the treatment of high-risk LBCL patients in the first-line setting and for patients with central nervous system involvement. Although CD19-CAR-T therapy has transformed the care of refractory/relapsed LBCL, about 60% of these patients will ultimately progress or relapse following CD19-CAR-T: therefore, it is fundamental to identify predictive criteria of response to CAR-T therapy and to develop salvage therapies for patients relapsing after CD19-CAR-T therapies. Moreover, ongoing clinical trials are evaluating bispecific CAR-T cells targeting both CD19 and CD20 or CD19 and CD22 as a tool to improve the therapeutic efficacy and to reduce the number of refractory/relapsing patients.

show abstract

Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

Cited by 10 publications

References 26 publications

Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?

Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?

Characteristics and prognosis of rrDLBCL with TP53 mutations and a high‐risk subgroup represented by the co‐mutations of DDX3X‐TP53

Car-T Cell Therapy in Large B Cell Lymphoma

Contact Info

Product

Resources

About